ImageneBio, Inc. (NASDAQ:IMA) Receives $26.50 Consensus PT from Analysts

Shares of ImageneBio, Inc. (NASDAQ:IMA) have been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $26.50.

IMA has been the subject of a number of research analyst reports. Wall Street Zen downgraded ImageneBio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Zacks Research cut ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Leerink Partners initiated coverage on shares of ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Wedbush downgraded shares of ImageneBio from a “neutral” rating to an “underperform” rating in a research report on Tuesday, November 25th. Finally, Leerink Partnrs raised shares of ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th.

Insider Activity

In other news, Director Joseph P. Slattery bought 16,000 shares of ImageneBio stock in a transaction dated Wednesday, December 24th. The stock was bought at an average cost of $5.99 per share, for a total transaction of $95,840.00. Following the purchase, the director directly owned 16,000 shares in the company, valued at approximately $95,840. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.94% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC acquired a new stake in ImageneBio in the third quarter valued at approximately $104,000. NewEdge Advisors LLC bought a new position in shares of ImageneBio in the 3rd quarter worth $106,000. Jacobs Levy Equity Management Inc. bought a new position in shares of ImageneBio in the 3rd quarter worth $144,000. Aldebaran Capital LLC acquired a new stake in ImageneBio in the 3rd quarter valued at $159,000. Finally, Squarepoint Ops LLC bought a new stake in ImageneBio during the 3rd quarter valued at $197,000. 75.00% of the stock is owned by institutional investors and hedge funds.

ImageneBio Stock Up 1.3%

IMA stock opened at $6.94 on Wednesday. The firm has a market cap of $77.59 million, a price-to-earnings ratio of -0.86 and a beta of 0.43. The company’s fifty day simple moving average is $6.97 and its 200 day simple moving average is $10.37. ImageneBio has a 12-month low of $5.70 and a 12-month high of $19.32.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by ($1.44). Research analysts expect that ImageneBio will post -0.91 earnings per share for the current year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.